Fas and FasL in plasma were determined by ELISA in 2 cohorts of CAD patients; one longitudinal study measuring circulating NK cells and apoptotic NK cells by flow cytometry 1 day, 3 months and 12 months after a coronary event and one cross-sectional study measuring NK cell apoptosis ex vivo. Both studies included matched healthy controls. Fas and FasL were also determined in supernatants from NK cells undergoing cytokine-induced apoptosis in cell culture.
Introduction
Inflammation is considered an important component in the atherosclerotic process. It is present not only in the vessel wall but also in the circulation. Patients with coronary artery disease (CAD) show systemic signs of chronic low-grade inflammation but moreover, they exhibit a perturbed immune homeostasis involving circulating leukocytes (1, 2) . It has been shown by several, including our own group, that the circulating levels of natural killer (NK) cells as well as the NK cell activity are reduced in CAD patients compared with healthy subjects, the reduction being more pronounced in patients with unstable conditions (3) (4) (5) (6) .
However, this is necessarily not a permanent feature. NK cells show a biological variation over time (7) and in a recently published 12-month follow-up study of patients with a coronary event, we demonstrated that NK cell levels could be restored to levels similar to controls (8) .
The mechanism behind the deficit of NK cells in CAD is mainly unknown but an increased apoptosis of NK cells in CAD patients has been reported (5, 9) . Activation-induced lymphocyte apoptosis is largely mediated through the extrinsic pathway involving surfacebound receptors. One major pathway involves the death receptor Fas which induces apoptosis after interacting with the Fas ligand (FasL). Soluble forms of Fas (sFas) and FasL (sFasL) are detected in plasma and frequently used as markers of apoptosis. In neoplastic and autoimmune diseases, the levels of sFas and sFasL have been positively related to circulating levels of apoptotic NK cells and T cells (10) (11) (12) . Interestingly, sFasL levels have also been positively associated with NK cell levels in NK cell proliferative disorders (13, 14) . In regard 5 to cardiovascular disease, high levels of sFas in plasma seem to indicate an increased risk (15) (16) (17) while elevations in sFasL rather represent a profile of low cardiovascular risk (15, 18, 19) .
The relationship between sFas or sFasL and lymphocyte apoptosis or lymphocyte levels in CAD is unknown.
Here, our aim was to investigate whether sFas and sFasL were positively related to NK cell apoptosis and NK cell levels in patients with acute and stable conditions of CAD, hypothesizing that these apoptotic markers could reflect the NK cell status in disease.
Methods

Subjects
Two independent cohorts of CAD patients (Cohorts I and II) were analysed. In Cohort I, 31 patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) and 34 patients with stable angina (SA) were consecutively recruited from the Department of Cardiology, University Hospital, Linköping, Sweden. NSTE-ACS patients were included if they had a diagnosis of non-ST elevation myocardial infarction, with the diagnosis based on typical ECG changes (ST-T segment depression and/or T-wave inversion) and elevated troponins. SA patients were included if they were referred for elective coronary angiography due to effort angina class II or III in accordance with Canadian Cardiovascular Society Classification and objective signs of ischemia obtained by exercise testing or myocardial perfusion imaging.
Blood samples at day 1 were collected immediately before coronary angiography and in 6 NSTE-ACS patients within 24 h from admission. Longitudinal measures were available in 15 NSTE-ACS patients and 28 SA patients, blood samples being collected at 3 and 12 months.
In Cohort II, 16 CAD patients who had suffered a coronary event (NSTE-ACS and/or coronary revascularization procedure) 3-6 months earlier were consecutively recruited from the same cardiology department as Cohort I. Patients in Cohort II were recruited before the inclusion in Cohort I started and none of the patients were included in both cohorts.
Patients were not eligible in any of the cohorts if they had severe heart failure, immunologic disorders, neoplastic disease, evidence of acute or recent (< 2 months) infection, recent major trauma, surgery or revascularization procedure, treatment with immunosuppressive or antiinflammatory agents (except low-dose aspirin).
In parallel with the recruitment of Cohort I and II, age and gender matched control subjects from the region were randomly invited from the Swedish Population Register. None of the controls participated in both studies. Subjects who accepted the invitation were included as controls if they were anamnestically healthy and received no medication. Anamnesis was gained by one dedicated nurse coordinator who also performed the blood sampling at the University Hospital´s Outpatient Cardiology Clinic.
The studies were conducted in accordance with the ethical guidelines of Declaration of Helsinki, and the research protocols were approved by the Ethical Review Board of Linköping University. Written informed consent was obtained from all patients and controls before blood collection.
Whole blood flow cytometric analysis of NK cells and T cells and their levels of apoptosis
In Cohort I, circulating levels of NK cells and T cells as well as apoptotic NK cells and T cells were assessed by whole blood flow cytometry within 1 hour from blood sampling. Cells were identified by using the following monoclonal antibodies: anti-CD3-fluorescein isothiocyanate (FITC) and anti-CD56-allophycocyanin (APC), both purchased from BD Biosciences (San José, CA, USA). As previously described (6, 8) , whole blood and antibodies were incubated for 15 minutes at room temperature, erythrocytes were thereafter lysed with 
Spontaneous NK cells and T cell apoptosis ex vivo
In Cohort II, the susceptibility to apoptosis of NK cells and T cells was determined in ex vivo assays. Blinded analyses were performed involving one patient and one age-and gendermatched control in each experimental set-up. Fractions of isolated NK cells or T cells were cultured in RPMI culture medium supplemented with 10 % FBS, 2 mM L-glutamine, 100 µg/mL penicillin G and 100 µg/mL streptomycin. The cells were cultured at 95 % air and 5 % CO 2 in a humidified atmosphere at 37º C for 18 hours. Thereafter, cells were collected, washed once and stained for 10 minutes on ice with annexin V-FITC and propidium iodide (Roche Diagnostics GmbH, Mannheim, Germany). Finally, samples were analysed on Becton-Dickinson LSR II Flow Cytometer using CellQuest software (10 000 cells were analysed in each sample). The number of apoptotic cells were also measured directly after isolation and used as a baseline reference. Quality assurance procedures using standard operating practice and Spherotech 8-peak validation beads (Becton Dickinson) every second week ensured reproducibility.
Cytokine-induced apoptosis of NK cells and T cells in vitro
The ability of NK cells and T cells to secrete Fas or FasL upon cytokine-induced apoptosis was determined in vitro. NK cell and T cell fractions were isolated from 5 healthy blood donors (according to the procedure described above), plated at 100 000 cells per well in 96- 
Measurements of Fas, FasL and interleukin-6 in plasma and after stimulation in vitro
Concentrations of Fas and FasL were determined in plasma samples from Cohort I and II and in cell supernatants after in vitro release by using Quantikine® ELISA kit (R&D systems, Abingdon, UK) following the manufacturer´s instructions. Quantifications of IL-6 were done in plasma samples from Cohort I by using QuantiGlo® Chemiluminescent ELISA (R&D systems) following the manufacturer´s instructions and the plates were read in a luminometer (Biotek, Germany). The limits of detection were as follows; Fas and FasL both 7.8 pg/mL and IL-6 0.48 pg/mL. Interassay coefficients or variation were < 3 %, < 10 % and < 5 % for Fas, FasL and IL-6, respectively. Samples were analyzed in duplicate with an intra-assay coefficient of variance for Fas, FasL and IL-6 of 7.5 %, < 8.0 % and < 15 %, respectively.
Statistical analyses
IBM SPSS Statistics 19 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.
The Pearson´s chi-square test and Mann-Whitney U-test were used for analyses between two groups and Kruskal-Wallis one-way analysis of variance for comparison between 3 groups.
The differences between related samples were analysed by Friedman´s test. Bivariate correlations were analysed by Spearman´s rank correlation coefficient. Statistical significances were set at a two-tailed p-value of < 0.05. Values are given as median (interquartile range).
Results
Plasma levels of sFasL are associated with recovery of NK cell levels in CAD patients (Cohort I)
Clinical and laboratory characteristics of Cohort I with age and gender matched controls are summarised in Table 1 . Compared with controls, the prevalence of smoking was higher in NSTE-ACS and SA patients. Also, the waist circumference was larger in both patient groups.
None of the controls were treated with antihypertensive drugs or statin. In the SA group, LDL cholesterol levels were lower than in NSTE-ACS and controls while triglyceride levels were higher in both patient groups. Also, IL-6 levels were higher in NSTE-ACS and SA patients than in controls, 4.3 (2.2-7.7), 3.2 (2.0-6.5) and 1.4 (1.0-2.2) pg/ml, respectively, p < 0.001.
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The levels of sFas, sFasL and subsets of NK and T cells are presented in Table 2 . At day 1, the levels of sFas were similar across groups while sFasL levels were lower in NSTE-ACS patients compared with SA patients and controls. In the total lymphocyte population, the proportions of NK cells were lower in both NSTE-ACS and SA patients compared with controls. In the NK cell population, the proportions of early apoptotic (annexin V+/7-AAD-) cells were low in all groups ( Table 2 ). Late-stage apoptotic or already dead lymphocyte subsets (annexin V+/7-AAD+) were not detectable in any blood samples. 
Plasma levels of sFasL are associated with increased susceptibility to NK cell apoptosis in CAD patients (Cohort II)
All patients in Cohort II were recruited 3-6 months after a coronary event thus being in a similar clinical stage as Cohort I during follow-up. In pairwise experiments, spontaneous apoptosis of freshly isolated NK cells and T cells was compared in 16 patients and 16 age and gender matched healthy controls. Besides a brief summary of participants´ clinical characteristics, Table 4 shows the plasma levels of sFas and sFasL and the apoptotic susceptibility of NK cells and T cells. The levels of sFas or sFasL did not differ between groups. NK cells from patients were significantly more susceptible to apoptosis compared with NK cells from controls. T cells, on the other hand, were less prone to apoptosis compared with NK cells with no difference between groups. In patients, the levels of sFasL were significantly correlated with susceptibility to NK cell apoptosis (r = 0.54, p < 0.05, see 
Discussion
In the present study, we provide evidence for a dynamic relationship between sFasL and NK cells in CAD patients. The novel findings can be summarized as follows: 1) plasma levels of sFasL were associated with recovery of NK cell levels in patients after a coronary event, 2) sFasL in plasma was associated with increased susceptibility to NK cell apoptosis in CAD patients and 3) apoptotic NK cells were themselves found to be a source of FasL.
14 The reduction of NK cells in CAD patients is well documented (3-6) and has been attributed to increased apoptosis of these cells (5, 9) . However, the increase in circulating NK cells that occurs in CAD patients after a coronary event (8) may also indicate an increased proliferation of these cells. A balance between apoptotic and proliferative rates is critical for maintaining homeostasis and normally, increased proliferation of cells is linked to increased apoptosis.
Although FasL is best known for its death-inducing function and as such, is considered a marker of apoptosis, it also has a role as signaling receptor in proliferation (21) (22) (23) . The association between sFasL and NK cell recovery in patients after a coronary event suggests that sFasL not only reflects an increased apoptotic rate but rather an increased apoptotic/proliferative rate of NK cells. Interestingly, previous studies have shown that plasma levels of sFasL are increased in NK cell proliferative disorders but not in other lymphoproliferative disorders like T cell leukemia or T and B cell lymphoma (13, 14) .
Furthermore, the high sFasL levels in NK cell proliferative disorders become normalized after chemotherapy when NK cell levels decline (14) .
In the present study, there were no correlations between sFas or sFasL and circulating apoptotic lymphocytes in CAD patients at any time point. Such correlations have been reported in gastric cancer (10, 11) as well as in systemic lupus erythematosus (12). In the studies of gastric cancer, remarkably high proportions of apoptotic NK cells and CD8+ T cells in blood were reported, 20 % in patients and 10 % in healthy controls (10, 11) . In the study by Courtney et al (12), 4 % of lymphocytes were apoptotic in patients with systemic lupus erythematosus compared with 1 % in controls. Since apoptosis is a time-sensitive process, we always performed flow cytometry within 1 hour from blood sampling. We found low numbers of apoptotic NK cells and T cells in both CAD patients and controls, similar to levels that were reported in healthy controls by Courtney et al (12) . However, when apoptosis was assessed ex vivo, we found that NK cell apoptosis was increased in CAD patients compared with controls. Moreover, susceptibility to NK cell apoptosis was significantly associated with plasma sFasL in patients, but not in control subjects, supporting the hypothesis that sFasL is associated with NK cell apoptosis under disease conditions.
Both NK cells and cytotoxic T cells are potential sources of sFasL (21, 22, 24) . To further evaluate this, we isolated human NK cells and T cells and compared their capacity to release FasL upon cytokine-induced apoptosis. In the 48-hour stimulation assay, the NK cell release of FasL was particularly abundant indicating that apoptotic NK cells themselves may be a prominent source of sFasL.
In previous studies, sFasL has emerged as a possible atheroprotective marker. Blanco-Colio et al (19) showed a positive correlation between sFasL levels and forearm reactive hyperemia in patients with CAD speculating that normal endothelial cells contributed to circulatory levels of sFasL. Furthermore, low levels of sFasL have been reported in patients with manifest CAD as well as in individuals at high cardiovascular risk (17, 18) . FasL is cleaved from the cell membrane to produce a soluble form. In contrast to membrane-bound FasL, the soluble form has been associated with anti-apoptotic and anti-inflammatory effects. In experimental settings, the soluble form is 1000-fold less active than the membrane-bound form (22) and moreover, it has been shown to antagonize the effects of membrane-bound FasL by competitive binding to Fas without inducing apoptosis (25) . It may be tempting to speculate that an increase in sFasL is needed to counteract enhanced apoptosis of NK cells in order to raise and/or maintain the levels of NK cells. Our results indicate that NK cells themselves are a potential source of sFasL in the circulation. During the cardiac rehabilitation phase, it is also possible that sFasL is released by endothelial cells as an indicator of improved endothelial function (19) . Improved endothelial function is associated with an improved inflammatory state, which in its turn may raise NK cell levels. Based on experimental studies, an inflammatory milieu has been associated with inhibited NK cell development and shortened survival of NK cells (26) .
The descriptive study design is one limitation of our study. Another limitation is the small size of study populations. We were thus not able to investigate the impact of possible confounders, such as smoking, hypertension or diabetes, on sFas or sFasL levels. On the other hand, the patient cohorts recruited at one single site were well characterized and treated according to current guidelines. The combined use of longitudinal analyses of circulating cells and ex vivo analyses may also be considered a strength.
To summarize, we show for the first time that sFasL in plasma is associated with an increased susceptibility to NK cell apoptosis in CAD patients and also, that an increase in sFasL following treatment of a coronary event is associated with an increase in circulating NK cells.
Our findings link NK cell status to a soluble marker with possible atheroprotective effects and may thereby support a beneficial role for NK cells in CAD. It remains to be confirmed in larger studies of CAD patients that sFasL is useful to monitor changes in NK cell levels. Also, it needs to be evaluated in prospective studies whether an increase of sFasL after a coronary event is a good prognostic sign. 
